A 6‐month randomized open‐label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder
Authors:
- 7 August 2007
- journal article
- research article
- Published by Wiley in Acta Psychiatrica Scandinavica
- Vol. 116 (s434) , 50-56
Abstract
Objective: To determine the safety and effectiveness of long‐acting injectable risperidone (LAI‐ris) add‐on in bipolar patients.Method: A 6‐month, open‐label, randomized, pilot trial enrolled 49 bipolar out‐patients who were taking a mood stabilizer and an atypical antipsychotic (AAP). Patients were maintained on a mood stabilizer and were randomized to continuation of their current AAP or switched to LAI‐ris treatment. Safety outcomes included adverse events and changes in vital signs, laboratory tests and extrapyramidal symptoms (EPS). Effectiveness measures included Clinical Global Impression‐Severity, scales assessing mania, depression, anxiety, resource utilization, quality of life, subject satisfaction with treatment, and time to intervention.Results: Twenty‐three subjects were randomized to LAI‐ris and 26 to oral AAP. There were no significant differences between the groups in adverse events, EPS change scores, weight or other safety measures. LAI‐ris group had significant reductions in symptoms as measured by changes in Clinical Global Impression‐Severity scores and Young Mania Rating Scale at endpoint relative to baseline and oral AAP group had reductions in Hamilton Anxiety Rating Scale scores relative to baseline but no significant differences were noted between the groups on any of the efficacy measures.Conclusion: LAI‐ris demonstrated similar effectiveness, safety and tolerability compared to oral AAP in this 6 month pilot trial.Keywords
This publication has 22 references indexed in Scilit:
- Olanzapine Versus Lithium in the Maintenance Treatment of Bipolar Disorder: A 12-Month, Randomized, Double-Blind, Controlled Clinical TrialAmerican Journal of Psychiatry, 2005
- A Randomized, Double-Blind, Placebo-Controlled Trial of Quetiapine in the Treatment of Bipolar I or II DepressionAmerican Journal of Psychiatry, 2005
- Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversiesBipolar Disorders, 2005
- Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorderJournal of Affective Disorders, 2004
- Enhancement of Treatment Adherence Among Patients With Bipolar DisorderPsychiatric Services, 2004
- Long-Acting Injectable Risperidone: Efficacy and Safety of the First Long-Acting Atypical AntipsychoticAmerican Journal of Psychiatry, 2003
- Nonadherence With Mood StabilizersThe Journal of Clinical Psychiatry, 2002
- A Comparison of Risperidone and Haloperidol for the Prevention of Relapse in Patients with SchizophreniaNew England Journal of Medicine, 2002
- Using Drug Claims Data to Assess the Relationship of Medication Adherence With Hospitalization and CostsPsychiatric Services, 2001
- Lithium use and discontinuation in a health maintenance organizationAmerican Journal of Psychiatry, 1996